A
Altus Lifescience
  • 3897

    Reproductive Medicine/ Maternal Health: Long-term implications of Covid on routine women’s health checkups? How effective virtual care be in diagnosing women’s health?


    Routine women’s health checkups like mammograms or pap smears require a physical interaction between a doctor and a patient. With Covid, all such routine examinations took a back seat. Now with the expansive growth of virtual care companies, the question remains if virtual gynecological appointments are good enough? Covid might be an excuse but we need to find solutions to address routine check-ups challenges for women when they are in remote areas or in communities where these topics are taboo.

  • 3900

    Global Health/ Deep Medicine: How to overcome the challenges of gathering women’s health data in diverse ethnic groups?


    Collecting women’s health samples and data from various countries in the Middle East, South Asia, Africa, Latin America, etc. is challenging. The genetic data sets or biomarkers in GWAS are predominantly from European or Caucasian ancestry. What will it take to come up with a collaboration where academic research institutions and organizations join hands to gather the sample data which can help create new tools and tests to address women’s health needs especially in reproductive health or oncology and beyond.


C
Cambridge Digital Health
  • 3902

    Gaming your research: are gamified apps the key to better study participant recruitment and retention?


    Women make up the majority of users on many of the most popular mobile game platforms.This workshop will explore whether there are ways to support research in women’s health by improving study participant engagement and retention through apps based on the same game theory. We will look at the key factors in mobile gaming that get people to engage and continue to do so for extended periods. We will explore how this can be practically applied in a mobile app that can meet the data collection goals of a study or trial, whilst providing benefit and reward to the user, and discuss the potential benefits and pitfalls of this approach.

  • 3905

    Pre-eclampsia and recurrent miscarriages: how can mobile apps help in providing better support?


    This workshop will explore whether a mobile app could be helpful in providing reassurance, advice and reliable information for women experiencing recurrent miscarriage, tailored to the different stages of the cycle of hope, anxiety and grief that many women go through. It will also explore the use of apps in supporting women with potentially serious pregnancy conditions such as pre-eclampsia, which require careful monitoring and patient education to reduce risk. We will explore important app features, the potential for external device integration and the benefits and potential challenges of creating these apps.


D
Daye
  • 3941

    What’s the role of cannabinoids in managing chronic and recurrent female pain?


    Cannabis has been used for medicinal purposes for thousands of years. The prohibition of cannabis in the middle of the 20th century has arrested cannabis research. In recent years there is a growing debate about the use of cannabis for medical purposes. The term ‘medical cannabis’ refers to physician-recommended use of the cannabis plant and its components, called cannabinoids, to treat disease or improve symptoms. Chronic pain is the most commonly cited reason for using medical cannabis. Cannabinoids act via cannabinoid receptors, but they also affect the activities of many other receptors, ion channels and enzymes. Preclinical studies in animals using both pharmacological and genetic approaches have increased our understanding of the mechanisms of cannabinoid-induced analgesia and provided therapeutical strategies for treating pain in humans. The mechanisms of the analgesic effect of cannabinoids include inhibition of the release of neurotransmitters and neuropeptides from presynaptic nerve endings, modulation of postsynaptic neuron excitability, activation of descending inhibitory pain pathways, and reduction of neural inflammation. Recent meta-analyses of clinical trials that have examined the use of medical cannabis in chronic pain present a moderate amount of evidence that cannabis/cannabinoids exhibit analgesic activity, especially in neuropathic pain.

  • 3944

    The role of the vaginal microbiome in fertility and pregnancy outcomes


    Indigenous and probiotic lactobacilli express properties antagonistic to pathogens, but complementary to host immunity. These organisms are associated with conception, reducing the risk of infection, as well as potentially lowering the risk of a number of complications of pregnancy that otherwise lead to maternal and infant mortality and morbidity.


E
ENDODIAG
  • 3929

    How to investigate diagnostic biomarkers when the endometriosis reference test, which associates a visualization of the lesions by laparoscopy followed by a histological confirmation, is imperfect and can miss positive patients ?


    Endometriosis is a chronic and disabling gynecological disease affecting 10% of women of reproductive age, representing 176 million patients in the world. It is defined as the presence of endometrial-like tissue outside the uterus, capable of invading several organs. It is associated with a variety of symptoms, mainly consisting of severe pelvic pain and infertility. It represents an annual economic burden estimated at $77,46 billion in 9 European countries and $78.05 billion in the USA. The current gold standard for diagnosis of endometriosis is invasive surgical laparoscopy enabling the visualization of the lesions by the surgeon and confirmation by a pathologist. This diagnosis takes in average 7 years. There is no cure. Medical therapy is palliative and surgical therapy has variable outcomes. Awareness of the disease is poor among practitioners and women see, in average, 7 physicians before endometriosis is suspected. Endodiag is an IVD company dedicated to reshape the journey of endometriosis patients. The company is specialized in the development of non-invasive diagnostic tests and has built an international regulatory compliant biobank (EndoBiobank®) of more than 1000 human biological samples, including positive endometriosis patients and controls.

  • 3932

    Where could a non-invasive diagnostic test for endometriosis fit in the medical journey of patients suffering from pain and/or infertility ?


    More specifically, where would such test a provide the more useful information for the patient ? Before or between imagery tests? What progress has been/can be made in identifying biomarkers of the two main symptoms of endometriosis, pain and infertility? Endometriosis is a chronic and disabling gynecological disease affecting 10% of women of reproductive age, representing 176 million patients in the world. It is defined as the presence of endometrial-like tissue outside the uterus, capable of invading several organs. It is associated with a variety of symptoms, mainly consisting of severe pelvic pain and infertility. It represents an annual economic burden estimated at $77,46 billion in 9 European countries and $78.05 billion in the USA. The current gold standard for diagnosis of endometriosis is invasive surgical laparoscopy enabling the visualization of the lesions by the surgeon and confirmation by a pathologist. This diagnosis takes in average 7 years. There is no cure. Medical therapy is palliative and surgical therapy has variable outcomes. Awareness of the disease is poor among practitioners and women see, in average, 7 physicians before endometriosis is suspected. Endodiag is an IVD company dedicated to reshape the journey of endometriosis patients. The company is specialized in the development of non-invasive diagnostic tests and has built an international regulatory compliant biobank (EndoBiobank®) of more than 1000 human biological samples, including positive endometriosis patients and controls.


F
Ferring Pharmaceuticals A/S
  • 3914

    Can you discuss molecular targets for improving outcomes in ART (or in the wider Reproductive medicine and maternal health space)?


    This is a very general question. We are engaged in drug discovery approaches for targeting improvments in assisted reproduction (amongst a much wider interest in reproductive medicine and maternal health), and would like to hear thoughts on appropriate targets or approaches in this space.


Fertility Circle
  • 3908

    Could a mobile application with psychosocial care features change the overall outcome for female IVF patients in terms of: a) Psychosocial wellbeing; b) Patient experience; c) IVF success rates?


    Technology could offer fertility clinics a way to support their IVF patient’s psychosocial wellbeing. Evidence relating to the optimal management of psychosocial care for IVF patients has been mixed to date. However, guidelines are offered by both ESHRE and HFEA. There is an opportunity to leverage technology alongside in-clinic face-to-face support to better support patients. Fertility Circle has a technology solution to deliver this and is looking for research partners to study its effectiveness. https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Psychosocial-care-guideline

    ESHRE psychology guideline_2015_final_version 1_2.pdf

  • 3911

    What features should be included in a mobile application designed to improve psychosocial wellbeing for women undergoing IVF and what further research is required to better define the recommendations for optimal psychosocial care?


    Technology could offer fertility clinics a way to support their IVF patient’s psychosocial wellbeing. Evidence relating to the optimal management of psychosocial care for IVF patients has been mixed to date. However, guidelines are offered by both ESHRE and HFEA. There is an opportunity to leverage technology alongside in-clinic face-to-face support to better support patients. Fertility Circle has a technology solution to deliver this and is looking to scope and test its offer as well as better understand the evidence base for this and study its effectiveness. https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Psychosocial-care-guideline

    ESHRE psychology guideline_2015_final_version 1_2.pdf


G
Gynica
  • 3915

    Cannabis & Women’s Health: Are the psychotropic effects of cannabis necessary when targeting physical, emotional and hormonal symptoms in women’s health disorders (menstrual pain, painful intercourse and endometriosis)?


    Gynica is specializing in clinically-validated, cannabinoids-based products in the field of women’s health. From ancient times, evidence suggests that medical cannabis has immense therapeutic potential in women’s health. The earliest references for its use can be found in ancient Mesopotamia, China, Persia, Israel, and Syria when women used it for menstrual pain, bloating, abnormal bleeding, menopausal symptoms, and urinary tract infections. We would like to discuss the different implications of cannabis use, and specifically THC – its controversial psychotropic compound, for the treatment of women’s health conditions.


M
MirZyme Therapeutics
  • 3639

    How can we make preeclampsia history within this decade?


    Preeclampsia is a hypertensive pregnancy disorder killing a mother or a baby every minute. Professor Ahmed’s group has over 20 years of research in preeclampsia who has discovered and patented accurate diagnostic and tailored therapy. The question is proposed to discuss how to use our current scientific understanding to solve preeclampsia.

  • 3642

    What are the values of academic and industry partnership in understanding women’s health?


    To accelerate translational research and overcoming the challenging environment for bioscience innovation, collaborations between industry and academia plays an important role. What values do we see in industry and academia partnership in improving R&D productivity and accelerating commercialisation?


N
Natural Cycles Nordic AB
  • 3917

    If you were given a device that measured skin temp., heart rate (HR), HR variability, pulse oximetry, movement and oxygen saturation in women, what research would you do in Women’s health with this data?


    Natural Cycles is currently testing a number of wearable devices on the market that measure a combination of biometrics for use with the product but with the possibility on collecting data and contributing to overall Women’s health research.

  • 3920

    Using continuous measurement devices, what other areas in overall health would you investigate relating to measurable biometrics to tailor treatment of all health conditions in women?


    Although Natural Cycles is focussed on contraception and pregnancy planning, once it has advanced in other areas of Women’s health, it aims to help women receive more tailored treatment for all health conditions unrelated to the reproductive system.


O
OCON Healthcare
  • 3933

    What would an ideal intrauterine device for developing countries look like?


    OCON Healthcare is a women’s health company that created the world’s first and only three-dimensional (3D) spherical copper intrauterine device (IUD) made from Nitinol, a super elastic alloy that can retain shape and is an ideal transporter of drugs to the uterus to treat various health conditions. The company develops, manufactures, and globally commercializes IUDs that are designed based on its proprietary Intra Uterine Ball (IUB™) platform, a novel technology that enables the development of technologically superior IUDs to address a myriad of women’s health issues. Discussion Points: – In which settings are IUDs currently inserted? – Who inserts IUDs? – Is there education about IUDs and family planning in general, if so, by whom? – Safety concerns and risks (malposition / perforation / ectopic pregnancy) -> difference of risk developed world vs. developing world (where ectopic pregnancies have high fatality rates) – Self-Removal of IUDs in the developing world:
    – What are possible obstacles? 
     – What are possible advantages?
     – What studies have been / can be done? – Other factors affecting IUD adoption rates (hormonal and non-hormonal)?

    OCON_Factsheet_Dec20.pdf

  • 3936

    What is the Clinical Environment in the developing world for a new paradigm of treatment of Global Endometrial Ablation (GEA) targeting Abnormal Uterine Bleeding (AUB) and/to tackle menstrual hygiene?


    OCON’s pipeline innovation the IUB™ SEAD™ (Spherical Endometrial Ablation Device) – currently in Ph2 clinical studies – is a non-invasive treatment for women suffering from heavy menstrual bleeding and/or abnormal uterine bleeding. This in-office, once-and-done, gentle ablation device is safer than the current standard of care for global endometrial ablation, which is invasive, expensive, and could cause uterine wall adhesions and/or hysterectomies. Discussion Points: – How is abnormal uterine bleeding currently treated in the developing world (drug and/or device) – What impact does it have on women and families 
 – What instruments are available
 – Access to training & education
 – Future opportunities with OCON’s SEAD 
- Possible obstacles

    OCON_Factsheet_Dec20.pdf

  • 3939

    What other indications and treatments could be possible with the Intrauterine Ball Platform Technology specifically looking at the developing world?


    OCON Healthcare is a women’s health company that created the world’s first and only three-dimensional (3D) spherical copper intrauterine device (IUD) made from Nitinol, a super elastic alloy that can retain shape and is an ideal transporter of drugs to the uterus to treat various health conditions. The company develops, manufactures, and globally commercializes IUDs that are designed based on its proprietary Intra Uterine Ball (IUB™) platform, a novel technology that enables the development of technologically superior IUDs to address a myriad of women’s health issues. – Uterine cancer – Myomas – Endometriosis – …

    OCON_Factsheet_Dec20.pdf


OneMedical Group
  • 3921

    Artificial Intelligence (AI) within Women’s Health technology – At what level do you stop automation in healthcare apps and engage a human decision?


    https://onemedicalgroup.co.uk/technology-and-insights/

  • 3924

    What are the biggest challenges/gaps within Women’s Health and what technology would help address these?


    https://onemedicalgroup.co.uk/technology-and-insights/


S
Syrona Health
  • 3647

    What is the best way to combine digital phenotypic patient reported data with multiomic datasets (genomic, proteomic, hormonal) for Chronic Gynaecological Conditions like, Endometriosis and PCOS?


    Syrona Health is collecting digital phenotypic patient-reported data through its flagship app ’SORA’ designed for those with Chronic Gynae Conditions.

  • 3650

    Validation of digital health technologies within a clinical trial?


    We will be running a clinical trial to further validate a digital therapeutic for our app and would like input with the design.

  • 3653

    How do you design a clinical trial for diagnostic utility of an app to triage high risk endometriosis patients, given that Endometriosis can only be confirmed through a laparoscopic surgery?


    How do you design a clinical trial for diagnostic utility of an app to triage high-risk endometriosis patients, given that Endometriosis can only be confirmed through a laparoscopic surgery?


V
Vira Health
  • 3927

    How should we assess the potential NHS savings for better menopause care and long term women’s health.


    Vira Health is a digital health company focused on relief for the central pain points of menopause. Their ultimate goal is to decrease the long-term disability suffered by women due to osteoporosis, cardiovascular disease and dementia, through better care at menopause. Their first product is an app called Stella, which delivers real relief for the critical pain points of menopause, including hot flushes, insomnia, weight gain, incontinence, and others. We would like to discuss the health economic impact on improving menopause care and preventing long term health conditions such as cardiovascular disease, Alzheimer’s and other neurodegenerative diseases and bone fractures from osteoporosis.